Skip to content

Evaluation of the clinical efficacy of Bixie Qianlie An Pill in the treatment of type III prostatitis patients

Evaluation of the clinical efficacy of Bixie Qianlie An Pill in the treatment of type III prostatitis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000579
Enrollment
Unknown
Registered
2024-10-21
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type III prostatitis kidney deficiency dampness heat and stasis

Interventions

control group:Type III A patients are given levofloxacin tablets
Type IIIB patients were given tamsulosin hydrochloride extended-release capsules.
Treatment group:BiXieQianLieAn pills

Sponsors

Henan Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) 18 years old< age < 50 years old; (2) Meet the diagnostic criteria of type III prostatitis; (3) TCM syndrome differentiation is consistent with kidney deficiency dampness heat and stasis obstruction syndrome; (4) The course of the disease is more than 3 months; (5) Those who received other treatments before the test should stop taking the drug for at least 2 weeks; (6) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with allergies allergies to this drug and those who cannot tolerate the drug; (2) Combined with interstitial cystitis glandular cystitis vesiculitis epididymitis digestive system diseases such as irritable bowel syndrome; (3) Combined with urinary tract infection benign prostatic hyperplasia bladder hyperactivity neurogenic bladder genital tract infection varicocele urinary stones urethral stricture urogenital tumors and other diseases; (4) Combined with prostate seminal vesicle tuberculosis lumbosacral hip joint and sports medicine-related diseases such as lumbar intervertebral disc herniation lumbar spondylolisthesis lumbar muscle strain etc. mental and psychological diseases pelvic floor muscle dysfunction; (5) Combined with severe cardiovascular and cerebrovascular diseases liver and kidney insufficiency hypotension and other diseases; (6) Those who have participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
National Insti-tutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI);

Secondary

MeasureTime frame
Traditional Chinese Medicine Syndrome Score;Expressed Prostatic Secretion Routine;Uroflow rate test;

Countries

China

Contacts

Public ContactSun Zixue

Henan Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Chinese Medicine)

sunhhzx@163.com13937105329

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026